Tag: AcT
Tenecteplase becomes first new stroke medicine to gain Health Canada approval...
Hoffmann-La Roche (Roche Canada) announced this week that Health Canada has granted market authorisation for its TNKase brand of tenecteplase—a thrombolytic agent—in the treatment...
Vision recovery among potential benefits of endovascular therapy in PCA occlusion...
A multicentre study presented at the recent European Stroke Organisation Conference (ESOC; 24–26 May, Munich, Germany) has found that vision recovery and an increased...
Tenecteplase offers “incredible opportunity” to optimise thrombolytic stroke treatments
Earlier this year, results from the Canadian AcT (Alteplase compared to tenecteplase) randomised controlled trial (RCT) were delivered for the first time at the...
